Verastem Quarterly Income Statements Chart
Quarterly
|
Annual
Verastem Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue: | |||||||||||||||||||||||
| sale of copiktra license and related assets | 649,000 | ||||||||||||||||||||||
| total revenue | 2,596,000 | 545,000 | 2,000 | 500,000 | 1,006,000 | 506,000 | 78,647,000 | 4,307,000 | 5,056,000 | 3,616,000 | 9,032,000 | 3,136,000 | 1,671,000 | 1,210,000 | 15,508,000 | 10,000,000 | |||||||
| yoy | 158.05% | 7.71% | -100.00% | -88.39% | -80.10% | -86.01% | 770.76% | 37.34% | 202.57% | 198.84% | -41.76% | -68.64% | |||||||||||
| qoq | 376.33% | 27150.00% | -99.60% | -50.30% | 98.81% | -99.36% | 1726.03% | -14.81% | 39.82% | -59.96% | 188.01% | 87.67% | 38.10% | -92.20% | 55.08% | ||||||||
| operating expenses: | |||||||||||||||||||||||
| research and development | 10,924,000 | 12,456,000 | 12,219,000 | 11,346,000 | 9,758,000 | 8,762,000 | 11,571,000 | 12,381,000 | |||||||||||||||
| selling, general and administrative | 7,363,000 | 7,399,000 | 7,329,000 | 6,106,000 | 6,421,000 | 6,514,000 | 5,934,000 | 5,660,000 | 5,523,000 | 6,714,000 | 6,218,000 | 7,095,000 | 20,614,000 | 15,442,000 | 19,604,000 | 23,728,000 | 22,153,000 | 29,298,000 | 26,033,000 | 26,199,000 | 25,426,000 | ||
| total operating expenses | 21,309,000 | 20,292,000 | 19,344,000 | 16,846,000 | 17,709,000 | 21,402,000 | 19,576,000 | 17,056,000 | 14,848,000 | 16,444,000 | 15,114,000 | 17,260,000 | 63,630,000 | 25,571,000 | 31,415,000 | 36,908,000 | 35,135,000 | 41,413,000 | 36,341,000 | 35,469,000 | 37,077,000 | 28,194,000 | |
| income from operations | -21,309,000 | -20,292,000 | -19,344,000 | -16,846,000 | -17,709,000 | -21,402,000 | -16,980,000 | -16,511,000 | -14,846,000 | -15,944,000 | -14,108,000 | -16,754,000 | 15,017,000 | -21,264,000 | -26,359,000 | -33,292,000 | -26,103,000 | -38,277,000 | -34,670,000 | -34,259,000 | -21,569,000 | -18,194,000 | |
| yoy | 20.33% | -5.19% | 13.92% | 2.03% | 19.28% | 34.23% | 20.36% | -1.45% | -198.86% | -25.02% | -46.48% | -49.68% | -157.53% | -44.45% | -23.97% | -2.82% | 21.02% | 110.38% | |||||
| qoq | 5.01% | 4.90% | 14.83% | -4.87% | -17.26% | 26.04% | 2.84% | 11.22% | -6.89% | 13.01% | -15.79% | -211.57% | -170.62% | -19.33% | -20.82% | 27.54% | -31.81% | 10.40% | 1.20% | 58.83% | 18.55% | ||
| operating margin % | -654.08% | -3029.54% | -742300.00% | -3188.80% | -1402.39% | -3311.07% | 19.09% | -493.71% | -521.34% | -920.69% | -289.01% | -1220.57% | -2074.81% | -2831.32% | -139.08% | -181.94% | |||||||
| other income | -1,313,000 | ||||||||||||||||||||||
| interest income | 2,247,000 | 1,122,000 | 976,000 | 111,500 | 316,000 | 84,000 | 46,000 | 40,000 | 40,000 | 49,000 | 52,000 | 18,000 | 19,000 | 122,000 | 356,000 | 611,000 | 1,005,000 | 1,268,000 | 1,497,000 | 1,306,000 | 763,000 | 343,000 | |
| interest expense | -1,129,000 | -1,121,000 | -769,000 | -724,000 | -717,000 | -640,000 | -56,000 | -10,000 | -7,980,000 | -1,007,000 | -975,000 | -1,354,000 | -1,898,000 | -1,868,000 | -10,674,000 | -5,452,000 | -5,041,000 | -5,185,000 | -4,929,000 | -3,952,000 | -862,000 | -516,000 | |
| change in fair value of preferred stock tranche liability | |||||||||||||||||||||||
| net income | -20,004,000 | -24,281,000 | -15,714,000 | -16,808,000 | -18,090,000 | -21,952,000 | -16,962,000 | -16,481,000 | -22,786,000 | -16,902,000 | -15,031,000 | -19,864,000 | 13,138,000 | -23,010,000 | -37,990,000 | -38,774,000 | -30,139,000 | -42,194,000 | -38,102,000 | -11,349,000 | -21,668,000 | -18,367,000 | |
| yoy | 10.58% | 10.61% | -7.36% | 1.98% | -20.61% | 29.88% | 12.85% | -17.03% | -273.44% | -26.54% | -60.43% | -48.77% | -143.59% | -45.47% | -0.29% | 241.65% | 39.09% | 129.73% | |||||
| qoq | -17.61% | 54.52% | -6.51% | -7.09% | -17.59% | 29.42% | 2.92% | -27.67% | 34.81% | 12.45% | -24.33% | -251.20% | -157.10% | -39.43% | -2.02% | 28.65% | -28.57% | 10.74% | 235.73% | -47.62% | 17.97% | ||
| net income margin % | -653.39% | -3024.04% | -1139300.00% | -3380.40% | -1494.14% | -3925.69% | 16.71% | -534.25% | -751.38% | -1072.29% | -333.69% | -1345.47% | -2280.19% | -937.93% | -139.72% | -183.67% | |||||||
| net income per share | -0.75 | -1.37 | -0.08 | -0.075 | -0.09 | -0.12 | -0.09 | -0.078 | -0.13 | -0.1 | -0.09 | -0.12 | 0.08 | -0.14 | -0.35 | -0.51 | -0.41 | -0.57 | -0.52 | -0.13 | -0.29 | -0.3 | |
| | |||||||||||||||||||||||
| weighted-average common shares outstanding used in computing net income per share—basic and diluted | 74,228 | 73,877 | 73,854 | ||||||||||||||||||||
| unrealized gain on available-for-sale securities | 48 | -5 | 6 | 39 | 91 | -17 | 5 | 53 | -9 | -13 | -59 | -24 | -17 | 125 | 4 | ||||||||
| comprehensive loss | -19,956 | -24,286 | -15,708 | -16,769 | -17,999 | -21,969 | -17,109 | -16,897 | -15,050 | -19,811 | 13,138 | -23,019 | -37,995 | -38,787 | -30,198 | -42,218 | -38,119 | -11,224 | -21,670 | -18,363 | |||
| transition services revenue | |||||||||||||||||||||||
| unrealized loss on available-for-sale securities | -147 | -19 | |||||||||||||||||||||
| product revenue | 134,000 | 5,829,000 | 4,235,000 | 5,034,000 | 3,617,000 | 4,032,000 | 3,019,000 | 1,671,000 | 1,210,000 | 508,000 | |||||||||||||
| license and collaboration revenue | 22,000 | -1,000 | 5,000,000 | 117,000 | |||||||||||||||||||
| cost of sales - product | 495,000 | 332,000 | 371,000 | 377,000 | |||||||||||||||||||
| cost of sales - intangible amortization | 392,000 | 392,000 | 392,000 | 392,000 | |||||||||||||||||||
| cost of sales - sale of copiktra license and related assets | |||||||||||||||||||||||
| weighted-average common shares outstanding used in computing: | |||||||||||||||||||||||
| unrealized (loss) on available-for-sale securities | -6.5 | -12 | |||||||||||||||||||||
| comprehensive income | -13,686.25 | -22,798 | |||||||||||||||||||||
| weighted-average common shares outstanding used in computing net income per share - basic and diluted | 108,153 | ||||||||||||||||||||||
| costs of revenues, excluding amortization of acquired intangible assets | 158,000 | 116,000 | 49,000 | ||||||||||||||||||||
| amortization of acquired intangible assets | 392,000 | 392,000 | 31,000 | ||||||||||||||||||||
| license revenue | 15,000,000 | 10,000,000 | |||||||||||||||||||||
| weighted-average number of common shares used in net income per share—basic and diluted | 73,644 | 61,256 | |||||||||||||||||||||
| general and administrative | 15,813,000 |
We provide you with 20 years income statements for Verastem stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Verastem stock. Explore the full financial landscape of Verastem stock with our expertly curated income statements.
The information provided in this report about Verastem stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.